Clinical Trial Update: Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

A combined Phase 2/Phase 3 trial investigating silymarin to mitigate chemotherapy toxicity and improve cognition in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cardiac Toxicity
• Cognitive Impairment
• Hepatic Toxicity
• Peripheral Neuropathy

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: Tanta University | Conditions: Breast Cancer, Peripheral Neuropathy | Phase 2, Phase 3 | Status: UNKNOWN